欧洲药品管理局人用药品委员会（CHMP）已确认其建议，拒绝批准对Hetlioz（塔西美尔通）营销授权的变更申请。该决定维持了委员会早前的立场，意味着相关制药公司——万达生物制药（Vanda Pharmaceuticals）——此次申请未获通过。
欧洲药品管理局人用药品委员会（CHMP）已确认其建议，拒绝批准对Hetlioz（塔西美尔通）营销授权的变更申请。该决定维持了委员会早前的立场，意味着相关制药公司——万达生物制药（Vanda Pharmaceuticals）——此次申请未获通过。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.